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Abstract 
Background: CD4+CD25highFOXP3+ regulatory T (Treg) cells, which include thymus‑derived and peripherally 
induced cells, play a central role in immune regulation, and are therefore crucial to prevent graft‑versus‑host disease 
(GVHD). The increasing use of allogeneic hematopoietic stem cell transplantation (allo‑HSCT) for elderly patients with 
thymus regression, and our case of allo‑HSCT shortly after total thymectomy, raised questions about the activity of 
thymus‑derived Treg cells and peripherally induced Treg cells, which are otherwise indistinguishable.
Results: We found that despite pre‑transplant thymectomy or older age, both naïve and effector Treg cells, as well 
as naïve and effector conventional T cells, proliferated in allo‑HSCT recipients. Higher proportions of total Treg cells 
1 month post allo‑HSCT, and naïve Treg cells 1 year post allo‑HSCT, appeared in patients achieving complete chimera 
without developing significant chronic GVHD, including our thymectomized patient, compared with patients who 
developed chronic GVHD.
Conclusions: Treg cells that modulate human allogeneic immunity may arise peripherally as well as in the thymus of 
allo‑HSCT recipients.
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Background
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT), including bone marrow (BM) transplantation 
(BMT), peripheral blood (PB) stem cell transplantation 
(PBSCT), and cord blood transplantation, is widely used 
for the treatment of malignant and nonmalignant hema-
tologic diseases [1]. However, allo-HSCT often shows 
comorbidity or mortality due to graft-versus-host disease 
(GVHD), opportunistic infections, regimen-related toxic-
ity and relapse of the original hematologic disease. Donor 
immune cells provide graft-versus-leukemia effects and 
protect against opportunistic infections. However, in 
GVHD, donor immune cells respond inappropriately to 
host antigens in a pro-inflammatory background of tissue 
damage and cytokine dysregulation [2].
Patients with acute GVHD (aGVHD) and chronic 
GVHD (cGVHD) show deficits of CD4+CD25high regu-
latory T (Treg) cells, which express the transcription fac-
tor, fork-head box P3 (FOXP3), and play a crucial role in 
control of autoimmunity [2, 3]. Treg cells usually derive 
from the thymus with upregulation of FOXP3. Thymus 
also provides naïve conventional T (Tcon) cells, which 
are considered to be crucial to maintain proper immune 
responses [4]. Therefore, therapeutic strategies that facili-
tate recovery of thymopoiesis have been attempted [5]. In 
addition, there is a second subset of Treg cells, periph-
ery-derived induced Treg cells (iTreg cells), which can 
be transformed from Tcon cells through upregulation 
of FOXP3 in the context of TGF-β and IL-2 [6–8]. It has 
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also been reported that alloantigen can induce Treg cells 
via a thymus-independent pathway in mice [9]. However, 
the role of iTreg cells in allo-HSCT is unknown because 
there is no known marker to discriminate iTreg cells 
from thymus-derived Treg cells.
After the introduction of reduced-intensity condition-
ing regimens, allo-HSCT increased for elderly patients, 
for whom the thymus is naturally regressed. In fact, 
delayed recovery of thymopoiesis, which can be inferred 
by T cell receptor rearrangement excision circle levels 
and naïve T cells, has been reported among elderly allo-
HSCT recipients [4]. Other investigators showed a more 
rapid reconstitution of effector T cells in allo-HSCT 
recipients older than 42  years compared with younger 
recipients [10]. In addition, even in patients with delayed 
recovery of thymopoiesis, clinical consequences of allo-
HSCT vary. Moreover, we recently encountered a case 
in which allo-HSCT for acute lymphoblastic leukemia 
shortly after thymectomy did not provoke significant 
GVHD. These facts prompted us to investigate the role 
of thymopoiesis after allo-HSCT, especially in relation 
to Treg cells. Hence, in this study, we investigated Treg 
and Tcon cells, including naïve and effector in allo-HSCT 
recipients in the context of patient age and cGVHD.
Results
Allo‑HSCT in young and old patients
We investigated 22 patients (Table  1), comparing clini-
cal findings and T cell populations between 14 young 
(<50 years) and 8 old (≥50 years) recipients. Old recipi-
ents more frequently received reduced-intensity condi-
tionings compared with young recipients [6/8 (75%) vs. 
2/14 (15%), P  =  0.038]. There was a trend that PBSCT 
was more common among old recipients (BMT vs. 
PBSCT, 3 vs. 5) compared with young recipients (11 
vs. 3) (P =  0.054). The thymectomized patient received 
PBSCT from an HLA allele fully matched related donor 
(30 year-old daughter) after reduced-intensity condition-
ing for acute lymphoblastic leukemia at complete remis-
sion. Her leukemia remains in complete remission at the 
time of evaluation, with 100% donor-derived cells in PB 
mononuclear cells (MNCs) and CD3+ cells, and BM 
MNCs. PB MNCs of all other patients were also in com-
plete chimera (>90% cells were donor-derived).
CD4+ conventional and regulatory T cells in young and old 
allo‑HSCT recipients early after transplantation
At day 30 after allo-HSCT, we performed 3-color flow 
cytometry, in which CD4+CD25highFoxp3+ lympho-
cytes and all other CD4+Foxp3− lymphocytes were 
defined as Treg cells and Tcon cells, respectively (Fig. 1a) 
[11]. Proportions of Tcon cells, rather than Treg cells, 
were significantly greater in young recipients compared 
with old recipients 1  month after allo-HSCT (Fig.  1b). 
Proportions of Treg cells were not correlated with ages 
of either recipients or donors (Fig. 1c), whereas there was 
a trend (P =  0.073) that proportions of Tcon cells were 
negatively correlated with recipient’s age, but not donor’s 
(Fig. 1d). On the other hand, we found that proportions 
of Treg cells were already lower at 1  month after allo-
HSCT in patients who eventually developed clinically 
significant cGVHD compared with those without (Fig. 2). 
There were no significant differences in proportions of 
Treg cells (0.24 ± 0.20 vs. 0.36 ± 0.42%) and Tcon cells 
(38  ±  19 vs. 23  ±  13%) between BMT recipients and 
PBSCT recipients. At this point, there were not any dif-
ferences in the absolute lymphocyte counts between 
young recipients and old recipients (0.59  ±  0.47 vs. 
0.56 ± 0.26 × 109/L), and both Treg cells and Tcon cells 
were already detectable in the thymectomized patient 
(Fig.  1a), who also had already achieved complete chi-
mera with 100% donor-derived PB MNCs and BM MNCs 
at this point.
Table 1 Patient characteristics
AML/MDS acute myeloid leukemia/myelodysplastic syndromes, ALL/ML 
acute lymphoblastic leukemia/malignant lymphoma, BMT bone marrow 
transplantation, PBSCT peripheral blood stem cell transplantation, HLA human 
leukocyte antigen, TBI total body irradiation, CY cyclophosphamide, BU Busulfan, 
Mel melphalan, GVHD graft-versus-host disease, CyA cyclosporine A, MTX 
methotrexate, TAC tacrolimus.
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Fig. 1 CD4+ regulatory T (Treg) and conventional T (Tcon) cells at 1 month after allo‑HSCT. a Flow cytometric analysis of the patient who had 
undergone thymectomy prior to PBSCT. Both CD4+CD25high Treg cells and CD4+ Tcon cells were among the CD4+ cells detected by flow cytom‑
etry of peripheral blood mononuclear cells at 1 month after PBSCT. Treg cells expressed Foxp3 more abundantly than Tcon cells. b Comparisons 
in the proportions of CD4+CD25highFoxp3+ Treg cells and CD4+Foxp3− Tcon cells between young and old allo‑HSCT recipients. Correlations 
between proportions of Treg cells (c) or Tcon cells (d) and ages of recipients or donors. The close circles indicate data of the thymectomized patient.
Fig. 2 Comparisons of Treg and Tcon proportions between allo‑HSCT recipients who eventually developed cGVHD and those without cGVHD. The 
close circles indicate data of the thymectomized patient.
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Naïve and effector T cells in allo‑HSCT recipients 1 year 
after transplantation
We studied proportions of naïve and effector fractions of 
Treg cells and Tcon cells (Fig. 3) [12], in young and old 
recipients at approximately 1  year after allo-HSCT. At 
this point, both in Treg cells and Tcon cells, CD45RA+ 
naïve cells remained at significantly low proportions in 
allo-HSCT recipients, regardless of age (Fig. 4). However, 
these naïve cells, as well as CD45RA− effector cells, were 
certainly detectable in all of these patients examined, 
even in the thymectomized patient (Fig. 3c), whose com-
plete chimera still persisted with 100% donor-derived PB 
MNCs and CD3+ lymphocytes, and BM MNCs at this 
point. Proportions of both naïve Treg cells and Tcon cells 
were not different between young and old recipients. We 
also compared proportions of Treg cells and Tcon cells 
with respect to cGVHD. In patients with clinically signifi-
cant cGVHD, we found significantly lower proportions of 
Treg cells, especially in the naïve fraction (0.015 ± 0.011 
vs. 0.049  ±  0.022%, P  =  0.024), compared with those 
without. In contrast, proportions of effector Tcon cells 
were significantly greater in patients with clinically signif-
icant cGVHD compared with other patients (34.0 ± 6.9 
vs. 20.2 ± 4.2%, P = 0.022).
Discussion
After allo-HSCT, the T-cell compartment is slowly recon-
stituted with both thymus-independent and -dependent 
pathways [4]. Early after transplantation, the thymus-
independent pathway by either adoptively transferred 
donor-derived T cells or recipient-derived T cells that 
survive conditioning treatment predominates. The trans-
ferred T cells expand in response to early post-transplant 
circumstances with lymphopenia and high cytokine lev-
els, and oligoclonal proliferation associated with cognate 
antigens. Another pathway, which is a more prolonged 
process of reconstitution of functional T cells with suf-
ficient and broad antigenic specificity, depends on the 
de novo production of naïve T cells by the thymus. Thus, 
thymic regeneration may be crucial to supply new Tcon 
cells and Treg cells that contribute to prevention of 
relapsing hematologic malignancies, opportunistic infec-
tions, and cGVHD [5, 13]. We found a lower frequency 
of Tcon cells rather than Treg cells early after allo-HSCT 
in the elderly recipients (Fig. 1). Our present study, how-
ever, revealed that naïve and effector Treg cells, as well 
as naïve and effector Tcon cells, exist even in allo-HSCT 
recipients more than 50  years old, including our surgi-
cally athymic patient, at 1 year after allo-HSCT (Fig. 3). 
Fig. 3 Detection of naïve and effector CD4+ cells in peripheral blood mononuclear cells. According to Ref. [14], naïve Tcon cells (fraction I), effector 
Tcon cells (II), naïve Treg cells (III), and effector Treg cells (IV) were CD4+ by flow cytometry. CD25 expression in each subpopulation is shown in the 
histogram. Representative data from a healthy donor, a patient with chronic GVHD (cGVHD), and our thymectomized patient are shown.
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The detailed kinetics of Treg cells is unclear in allo-
HSCT recipients, but proportions of naïve Treg cells 
and Tcon cells were lower in recipients compared with 
healthy controls, independent of recipient or donor age, 
at both 1 month and 1 year in the present study. Next, we 
observed lower frequencies of Treg cells at both 1 month 
and 1  year after allo-HSCT in patients who eventually 
developed clinically significant cGVHD, consistent with 
previous studies [14, 15]. Imanguli et  al. [16] recently 
compared proportions of naïve and effector Treg cells 
between patients with cGVHD and normal controls 
with the same method used in our present study [12]. 
They found significantly lower frequency of naïve Treg 
cells, but not effector Treg cells, in allo-HSCT recipients 
compared with controls. In our present study, regard-
less of the presence of cGVHD, allo-HSCT recipients 
consistently showed decreased naïve Tregs. Neverthe-
less, we found that proportions of Treg cells, especially 
Fig. 4 Comparisons in the proportions of naïve and effector Treg cells and Tcon cells between allo‑HSCT recipients and healthy controls. Propor‑
tions of indicated cells in allo‑HSCT recipients (R), determined by flow cytometry as shown in Fig. 3, were compared with age‑matched controls (C). 
The close circles indicate data of the thymectomized patient.
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in the naïve fraction, were significantly lower in patients 
with cGVHD compared with patients without cGVHD, 
despite a small cohort with heterogeneities including 
donor sources and conditioning protocols in the present 
study. Another concern of this study is that the thymec-
tomized patient belongs to the older group. These facts 
limit the confidence that can be placed in our findings. 
However, it has been recently reported that impaired 
reconstitution of naïve Treg cells was also associated with 
aGVHD [17] as well as cGVHD, lending support to the 
importance of naïve Tregs in the modulation of alloge-
neic immune phenomena that cause GVHD.
In patients who were coincidentally thymectomized 
through cardiac surgery, atopic and autoimmune-like 
symptoms with elevated anti-dsDNA antibodies were 
frequently found [18]. Such autoimmune-like diseases 
were associated not with total numbers of Treg cells, but 
Treg homeostasis preserved by naïve Treg cells in these 
post-surgery individuals with impaired thymopoiesis. In 
an established mouse model, female B6AF1 mice thymec-
tomized on day 3 develop autoimmune ovarian disease 
and dacryoadenitis [19, 20]. These mice possess disease-
relevant Treg cells of neonatal origin, which accumulate 
in the regional lymphoid tissues and inhibit autoimmune 
disease [20]. Although they cannot fully prevent devel-
opment of autoimmune diseases, the autoimmune dis-
eases are dramatically enhanced by in  vivo depletion of 
Treg cells in these mice. On the other hand, the role of 
thymic ablation in allogeneic immunity largely unknown, 
although we could speculate about the poor clinical con-
sequences of allo-HSCT recipients with delayed thymo-
poiesis in recipients with reduced pre-transplant thymic 
function and in patients suffering from acute or chronic 
GVHD [21–24]. There has been only a single case report 
of thymectomy followed by allo-HSCT for a patient with 
systemic lupus erythematosus, thymoma, and pure red 
cell aplasia [25]. Although this patient achieved clini-
cal remission of red cell aplasia and lupus, autoantibod-
ies did not disappear after allo-HSCT. It has also been 
reported that a murine model showed an extrathymic de 
novo generation of donor-derived T cells against murine 
cytomegalovirus, although these cells were numeri-
cally and functionally reduced compared with thymus-
derived T cells [26, 27]. These facts and the existence of 
naïve Treg cells and Tcon cells in our present study may 
together suggest that some T cells derived independent 
of the thymus contribute to immune reconstitution after 
allo-HSCT. In fact, our thymectomized patient, who had 
a 100% donor-derived CD3+ cell population including 
Treg cells, has not required systemic steroids for cGVHD 
without relapse of leukemia.
There are two types of Treg cells, thymus-derived natu-
ral Treg cells, and peripherally generated adaptive Treg 
cells (iTreg cells) [6–8]. Tcon cells can be converted to 
Foxp3+ iTreg cells, under the influence of IL-2, but not 
thymus. In addition, alloantigens can induce Tregs via 
a thymus-independent pathway in mice [9]. Successful 
allo-HSCT in our thymectomized patient offers strong 
evidence that peripherally derived adoptive Treg cells can 
proliferate, a phenomenon also supported by observa-
tion of Treg cells in elderly allo-HSCT recipients in the 
present study and another previously reported thymecto-
mized patient [25]. This might also partly explain the effi-
cacy of low-dose IL-2 administration [28], and support 
adoptive Treg cell infusion [29], although the functional 
difference of Treg cells among young, old and/or thymec-
tomized patients remain unclear. So far, there have been 
not any specific markers to distinguish natural Treg 
cells and iTreg cells, but naïve Treg cells observed in our 
thymectomized patient were considered to include iTreg 
cells. Indeed, it has been reported that Foxp3+ iTreg cells 
showed the characteristics of T-cell receptor repertoire 
of naïve Tcon cells [6]. The role of iTreg cells, in addition 
to strategies aiming thymic restoration [5, 13, 30], in allo-
HSCT should be further investigated.
Conclusions
Even with pre-transplant thymectomy or older age, both 
naïve and effector Treg cells certainly proliferated in allo-
HSCT recipients. This finding suggests that Treg cells, as 
well as Tcon cells, can arise peripherally to modulate allo-
geneic immune responses in humans.
Methods
Patients and controls
Twenty-two patients who underwent allo-HSCT from 
2008 through 2014, and survived without relapse of 
hematologic diseases at least 300  days after transplant, 
were included in this study. In 10 of 22 patients, partial 
results were previously reported [11]. Median age was 
38.5  years with 8 “old recipients” 50  years or older. We 
compared these old recipients with young recipients 
(<50  years) to estimate the contribution of age-related 
thymic involution to the reconstitution of T cells in allo-
HSCT. One patient, a 59-year-old female with acute 
lymphoblastic leukemia, had received total thymectomy 
to treat invasive thymoma 5 months prior to allo-HSCT.
Patients received tacrolimus and methotrexate as 
prophylaxis for GVHD, except three who received cyclo-
sporine and methotrexate. All patients received standard 
supportive treatments including use of laminar airflow 
units meeting allo-HSCT standards during myelosup-
pression, prophylaxis of viral infection with acyclovir, 
administration of granulocyte colony-stimulating fac-
tor, and blood transfusion, for which thresholds of 8  g/
dL hemoglobin and 20 ×  109/L platelets were generally 
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used for packed irradiated red cells and irradiated apher-
esis platelet concentrates, respectively. Incidences of 
cGVHD [31] were first diagnosed by standard criteria. 
Among patients with any cGVHD, we deemed clinically 
significant cGVHD as that requiring systemic steroid 
therapy with no less than 30 mg/day of prednisolone, as 
described elsewhere [14].
This study was approved by Ethics Review Board of 
Fukushima Medical University, which is guided by local 
policy, national law, and the Declaration of Helsinki. 
All investigations were performed after properly docu-
mented informed consent. Information and records of 
patients were anonymized and de-identified prior to 
analysis.
Samples
Peripheral blood samples were collected for flow cytom-
etry of Treg cells and Tcon cells at 1 month and/or 1 year 
after allo-HSCT as described previously [11]. In later 
evaluation at 1  year after allo-HSCT, we also evalu-
ated naïve and effector cell fractions of each cell type 
as recently described by Sugiyama et  al. [12]. Samples 
obtained from six age-matched healthy volunteers were 
used as controls.
Cell separation, flow cytometry, and chimerism analysis
Peripheral blood mononuclear cells were isolated using 
Ficoll-Hypaque (Lymphoprep; Axis-shield, Oslo, Nor-
way) and suspended in phosphate-buffered saline con-
taining 0.5% bovine serum albumin (Wako, Osaka, 
Japan). Anti-CD4 (OKT4; BioLegend, San Diego, CA, 
USA), anti-CD25 (B1.49.9; Beckman Coulter, Brea, CA, 
USA), anti-CD45RA (HI100; ALPCO Diagnostics, Salem, 
NH, USA) and/or anti-FOXP3 (PCH101; eBioscience, 
San Diego, CA, USA) were used to label PB MNCs after 
treatment with fixation Permeabilization Buffer (eBiosci-
ence). Non-specific control antibodies of the same sub-
classes were used as negative controls. These PB MNCs 
were counted by flow cytometry using a FACSCanto II 
(BD Biosciences), and the data were analyzed with Flow 
Jo software (FLOW JO LLC, Ashland, OR, USA). For chi-
merism analysis of CD3+ cells from the thymectomized 
patient, cells were sorted using EazySep T cell Enrich-
ment Kit (StemCell Technologies, Vancouver, BC, Can-
ada) according to the manufacturer’s protocol. The purity 
of CD3+ cells, evaluated by flow cytometry, was over 
99% in each sample.
Chimerism analysis
Chimerism of PB MNCs, sorted CD3+ cells, and BM 
MNCs was determined by short tandem repeat polymer-
ase chain reaction [32] for sex-matched transplants, or 
fluorescence in  situ hybridization for sex chromosomes 
for sex-mismatched transplants.
Statistical analysis
To compare categorical variables, the Chi square test was 
used. The comparison of continuous variables between 
two groups was made using the unpaired Student’s t-test. 
Correlation coefficient was calculated to determine the 
correlation between two parameters. All data are shown 
as mean  ±  standard deviation unless otherwise speci-
fied. All P values are two-sided, with P < 0.05 considered 
significant.
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